TCT-283 Intimal Hyperplasia and Vascular Remodeling after Everolimus-eluting and Sirolimus-eluting Stent Implantation in Diabetic Patients. The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound Trial  by Antonsen, Lisbeth et al.
TCT-281
The Association Between Cholesterol Crystal And Features Of Plaque
Vulnerability On Optical Coherence Tomography
Yu Kataoka1, Julie Thornton1, Kathy Wolski1, Rishi Puri1, James Harvey1,
Kiyoko Uno1, Samir Kapadia1, E. Murat Tuzcu1, Steven Nissen1, Stephen Nicholls1
1Cleveland Clinic, Cleveland, OH
Background: Cholesterol crystals are often seen abundantly within atheromatous
plaques and at sites of plaque disruption. Recent studies have demonstrated that
crystallization of cholesterol promotes volume expansion potentially, triggering plaque
rupture. However, the relationship between cholesterol crystals and other features of
plaque vulnerability has not been characterized. As optical coherence tomography (OCT)
enables the visualization of cholesterol crystals in vivo, we investigated the impact of
cholesterol crystals on plaque vulnerability by using OCT.
Methods: 102 patients with angiographic coronary artery disease underwent OCT
imaging of non-culprit lipid plaque. Cholesterol crystals were identified as a thin, linear
region with high signal intensity and backscattering. Patients with (n44) and without
(n58) cholesterol crystals were compared with regard to clinical characteristics and
OCT-derived features of plaque vulnerability.
Results: 43% of study population demonstrated cholesterol crystals in non-culprit
atherosclerotic plaque. Patients with cholesterol crystals were more likely to have a history
of myocardial infarction (41% vs. 22%, p0.04) and demonstrated higher leukocyte
counts (9362 /ul vs. 7911 /ul, p0.03). These patients more frequently received ACE-I
(64% vs. 38%, p0.009) and were less likely to be treated with a statin (52% vs. 32%,
p0.04). OCT demonstrated that patients with cholesterol crystals had a thinner fibrous
cap thickness and were more likely to contain plaque microchannels and lipid pools
(Table).
Conclusions: The presence of cholesterol crystals is associated with features of plaque
vulnerability on OCT. These patients require more intensive risk factor modification for
the prevention of future ischemic events.
Table.
Cholesterol
crystal (-)
(n58)
Cholesterol
crystal ()
(n44) p-value
myocardial infarction 41% 22% 0.04
ACE-I 38% 64% 0.01
Statins 52% 32% 0.04
Leukocyte /ul 7911 2585 9362 4309 0.03
FCT 98.6 62.0 um 71.9 25.8 um 0.03
Microchannel 39% 73% 0.001
Lipid-rich plaque
(quadrant  2)
52% 86% 0.001
TCFA 41% 58% 0.10
FCT  fibrous cap thickness, TCFA  thin-cap fibroatheroma.
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Background: The Combo Dual Therapy Stent (OrbusNeich Medical, Ft. Lauderdale,
FL, USA) combines low-dose sirolimus delivery from an abluminal biodegradable
polymer matrix along with a covalently bound anti-CD34 antibody layer in a combination
device designed for control of neointimal proliferation as well as to promote vessel
healing by stimulating endothelial repair. Optical coherence tomography (OCT) provides
important insight into morphology and mechanisms of vessel healing associated with the
implantation of intracoronary stents.
Methods: REMEDEE OCT (NCT01405287) is designed to assess the early vascular
healing of the Combo stent as compared to an everolimus eluting stent (EES) in patients
with Acute Coronary Syndrome (ACS: STEMI & non-STEMI) requiring treatment of
single, de novo native coronary artery lesions. REMEDEE OCT is a prospective,
multicenter, randomized study designed to enroll 60 ACS patients, randomized 1:1 to be
treated with the Combo stent versus an EES (XIENCE V, Abbott Vascular, Illinois USA
or PROMUS, Boston Scientific, Natick, MA, USA). All patients receive OCT and QCA
follow-up imaging at 60 days post procedure and clinical follow-up at 30, 60, 180, 360
and 540 days. QCA and OCT was performed at baseline and a subset of patients received
IVUS and assessment of circulating EPCs. The primary study endpoint is the OCT
assessment of the percentage of uncovered struts per stent at 60 days of the Combo stent
compared to its control. Secondary endpoints include OCT assessment of indices of
neointimal heterogeneity (optical density analysis), and clustering of uncovered and/or
malapposed struts. All OCT, QCA, EPC and IVUS data are measured and assessed by
independent Core Laboratories. Secondary clinical endpoints will also be reported.
Results: 60 subjects were consented and randomized in a 1:1 fashion at 6 investigative
sites in Europe.
Conclusions: The Combo Dual Therapy Stent is a new technology unique in its
combined mechanism of action. The REMEDEE OCT 60-day stent strut healing results
will be the first RCT evaluation of the effectiveness of the Combo Stent to influence
vascular healing.
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Background: Patients with diabetes mellitus have increased risk of in-stent restenosis
after coronary stent implantation due to intimal hyperplasia (IH). The aim of this study
(substudy of the SORT OUT IV trial), was to use volumetric intravascular ultrasound
(IVUS) to evaluate the effects of the everolimus-eluting Xience™/Promus™ stent (EES)
and the sirolimus-eluting Cypher™ stent (SES) on intima hyperplasia in diabetic patients.
Methods: In the DiabeDES IV IVUS trial, serial IVUS 10-month follow-up data were
available in 88 patients, including 48 EES and 40 SES treated patients. IVUS of the
stented segment and 5-mm long segments immediately proximal and distal to the stent
was performed after the procedure and at follow-up. IVUS endpoints included IH volume
and in-stent percent volume obstruction.
Results: Baseline clinical characteristics and lesion parameters were similar in the two
groups. As compared to the SES group, IH volume was increased in the EES group
[median (interquartile range): 2.8 mm3 (0.0 to 12.6) vs. 0.0 mm3 (0.0 to 1.1), p0.001].
In-stent % volume obstruction was increased in EES as compared to SES [median
(interquartile range): 1.6% (0.0 – 8.2) vs. 0.0% (0.0 – 1.0), p0.001]. Peri-stent external
elastic membrane (EEM) volume: (post procedure vs. follow-up EES [300 mm3
(219-491) vs. 307 mm3 (223-482); pns] and SES [316 mm3 (235-399) vs. 323 mm3
(246-404); pns]) and peri-stent plaque volume: EES [163 mm3 (103-273) vs. 184
mm3 (115-291); pns] and SES [186 mm3 (139-248) vs. 175 mm3 (153-243); pns])
were unchanged in both groups. In the distal reference and proximal reference, there were
no significant changes in reference-segment EEM, plaque or lumen volume in either of the
two stent groups.
Conclusions: In diabetic patients, EES stent implantation was associated with increased
IH volume obstruction compared to SES stent without involvement of vascular remod-
eling.
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Background: Also there are differences in the carotid and coronary vasculature, both
vascular distributions are believed to share common pathway in disease progression.
However, little is known about atherosclerotic plaque composition and morphological
differences between carotid and coronary artery disease. The aim of the study was to
determine correlation between intravascular ultrasound virtual histology (IVUS-VH)
defined atherosclerotic plaque components in coronary and carotid artery atherosclerotic
lesions.
Methods: In a single-center prospective study 100 consecutive patients (60 men and 40
women) with mean age 69.618.44 years were enrolled. All patients were scheduled for
carotid and/or coronary artery stenting and underwent IVUS-VH examination of coronary
and carotid plaque before intervention. Statistical comparison between coronary and
carotid artery plaque composition according to IVUS-VH was done with Pearson
correlation.
Results: High percentage of necrotic core was found both in coronary (22.557.30) and
carotid (19.849.35) artery plaques, r0.459, p0.001. Percentage of dense calcium
(13.588.15 vs. 7.675.64, r0.557, p0.001), fibrolipids (12.549.08 vs.
19.559.96, r0.379, p0.001) and fibrotic tissue (51.7210.33 vs. 53.427.95,
r0.422, p0.001) showed moderate, statistically significant correlation between coro-
nary and carotid arteries, respectively (Figure 1).
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